Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal CancerTakashi Kojima, Sung‐Bae Kim, Se‐Hoon Lee et al.|Journal of Clinical Oncology|2020Cited by 1.2k
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the EsophagusManish A. Shah, Ken Kato, Takashi Kojima et al.|JAMA Oncology|2018Cited by 518
Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based studyKuniko Sunami, Takashi Kohno, Hitoshi Ichikawa et al.|Cancer Science|2019Cited by 375
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studiesYoshiaki Nakamura, Takayuki Yoshino, Hiroya Taniguchi et al.|Nature Medicine|2020Cited by 366
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III StudyLin Shen, Ken Kato, Sung‐Bae Kim et al.|Journal of Clinical Oncology|2022Cited by 306